Atopic Dermatitis

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

Researchers found that abrocitinib demonstrated rapid, sustained, and deep improvements in several important domains of itch-dominant AD.

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Patients with AD experienced significant impacts to disease severity, disease control, and quality of life regardless of lesion location count.

A poster from the 2024 American Psychiatric Association Annual Meeting delved into the relationship between MDD and various dermatologic conditions.

Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.

Dr. Matthew J. Zirwas, evaluates a 45-year-old woman with worsening, highly itchy dermatitis on her hands and arms, notably her fingertips. He addresses management strategies for her condition, which has deteriorated over four months, leading to painful fissures

Matthew J. Zirwas, MD, , presents a complex case study of a 63-year-old male patient with atopic dermatitis presenting as a chronic, severe pruritic rash on his back, upper arms, and upper thighs. His condition has persisted consistently for the past three months despite a history of intermittent occurrences over several years.

A prebiotic cleanser and moisturizer regimen not only significantly alleviated the severity of atopic dermatitis and xerosis, but also uncovered crucial differences in symptom experiences.

The awarded grant will span a total of 3 years.

Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

The new research will compare eblasakimab to dupilumab and lebrikizumab.

A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.

A decision from the FDA is expected in the second half of 2024.

The FDA’s PDUFA date is expected in quarter 4 of 2024.

Mona Shahriari, MD, explores potential areas of research that can contribute to continuous improvement in pediatric atopic dermatitis management.

Mona Shahriari, MD, expands on benefits of ruxolitinib in managing itch and inflammation in pediatric atopic dermatitis.

In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.

Posters from the Academy of Managed Care Pharmacy annual meeting featured studies on atopic dermatitis.

Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.

LC-OCT provided quick, noninvasive assessment of skin conditions with detailed imaging aids diagnosis and treatment, especially for patients with darker skin types.

Michael Cameron, MD, identifies comorbidities, lifestyle factors, and educational opportunities AAD guidelines provide insight on for patients with atopic dermatitis.

Michael Cameron, MD, identifies the most important pearls from the latest atopic dermatitis treatment guidelines set forth by the American Academy of Dermatology.

Sonya Kenkare, MD, explains her approach to itch and the support system of multiple specialties to help a pediatric patient with atopic dermatitis.

Sonya Kenkare, MD, details where ruxolitinib fits within the current landscape of pediatric atopic dermatitis treatments.

Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.

Brad Glick, DO, MPH, FAAD, notes the absence of location restrictions with topical ruxolitinib cream, distinguishing it from topical corticosteroids. The panel discusses the cyclic pattern of steroid use and the potential of ruxolitinib cream as a continuous treatment option.